Package Leaflet: Information for the User
Bimzelx 160 mg solution for injection in pre-filled syringe
bimekizumab
This medicine is subject to additional monitoring, which will allow for quick identification of new safety information. You can help by reporting any side effects you may get. The last section of the leaflet includes information on how to report side effects.
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack
What is Bimzelx
Bimzelx contains the active substance bimekizumab.
What is Bimzelx used for
Bimzelx is used to treat the following inflammatory diseases:
Plaque psoriasis Bimzelx is used in adults to treat a skin condition called plaque psoriasis. Bimzelx reduces symptoms, including pain, itching, and skin scaling.
Psoriatic arthritis
Bimzelx is used to treat adults with psoriatic arthritis. Psoriatic arthritis is a disease that causes joint inflammation, often accompanied by plaque psoriasis. If you have active psoriatic arthritis, you may have been given other medicines first. If these medicines do not work well enough or if you cannot tolerate them, you will receive Bimzelx alone or in combination with another medicine called methotrexate.
Bimzelx reduces inflammation and can help reduce pain, stiffness, swelling in the joints and around them, psoriatic skin rash, and nail damage, as well as slow down cartilage and bone damage in the affected joints. These effects help control the signs and symptoms of the disease, make it easier to perform daily activities, reduce fatigue, and improve quality of life.
Axial spondyloarthritis, including non-radiographic axial spondyloarthritis and ankylosing spondylitis (radiographic axial spondyloarthritis)
Bimzelx is used to treat adults with a disease that mainly affects the spine and causes inflammation of the joints in the spine, called axial spondyloarthritis. If the condition is not visible on X-rays, it is called "non-radiographic axial spondyloarthritis"; if it occurs in patients with visible signs on X-rays, it is called "ankylosing spondylitis" or "radiographic axial spondyloarthritis".
If you have axial spondyloarthritis, you will first be given other medicines. If you do not respond well enough to these medicines, you will be given Bimzelx to reduce the signs and symptoms of the disease, decrease inflammation, and improve your physical functional ability. Bimzelx can help reduce back pain, stiffness, and fatigue, making it easier to perform daily activities and improve quality of life.
Hidradenitis suppurativa
Bimzelx is used in adults to treat a disease called hidradenitis suppurativa (sometimes referred to as inverse acne or Verneuil's disease). Hidradenitis suppurativa is a chronic inflammatory skin disease that causes painful lesions in the form of nodules (lumps) and abscesses (boils), as well as lesions that can ooze pus. It mainly affects specific areas of the skin, such as under the breasts, armpits, inner thighs, groin, and buttocks. Scars can also form in the affected areas. You will first be given other medicines. If your response to these medicines is not sufficient, you will be given Bimzelx.
Bimzelx reduces inflammatory nodules (lumps), abscesses (boils), and lesions that can ooze pus, as well as pain caused by hidradenitis suppurativa.
How Bimzelx works
Bimekizumab, the active substance in Bimzelx, belongs to a group of medicines called interleukin inhibitors (IL). Bimekizumab works by reducing the activity of two interleukins called IL-17A and IL-17F, which are involved in the production of inflammation. The levels of these interleukins are elevated in inflammatory diseases such as psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa.
Do not use Bimzelx
If you have a serious infection that your doctor considers important, such as tuberculosis (TB).
Warnings and precautions
Talk to your doctor, pharmacist, or nurse before starting Bimzelx if:
Inflammatory bowel disease (Crohn's disease or ulcerative colitis)
Stop using Bimzelx and tell your doctor or seek medical attention immediately if you notice blood in your stool, abdominal cramps, pain, diarrhea, or weight loss. These may be signs of the onset or worsening of inflammatory bowel disease (Crohn's disease or ulcerative colitis).
Be aware of the risk of infections and allergic reactions
On rare occasions, Bimzelx can cause serious infections. Talk to your doctor or seek medical attention immediately if you notice any signs of a serious infection. These signs are listed in "Serious side effects" in section 4.
Bimzelx can cause serious allergic reactions. Talk to your doctor or seek medical attention immediately if you notice any signs of a serious allergic reaction. These signs may include:
Children and adolescents
This medicine must not be used in children and adolescents under 18 years of age, as it has not been studied in this age group.
Other medicines and Bimzelx
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.
Pregnancy, breastfeeding, and fertility
If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine. It is recommended to avoid using Bimzelx during pregnancy, as it is not known how this medicine will affect the baby.
If you are a woman who can become pregnant, you must use contraception while using this medicine and for at least 17 weeks after the last dose of Bimzelx.
If you are breastfeeding or plan to breastfeed, ask your doctor for advice before taking this medicine. You and your doctor will decide whether you can breastfeed or use Bimzelx.
Driving and using machines
Bimzelx is unlikely to affect your ability to drive or use machines.
Bimzelx contains polysorbate 80
This medicine contains 0.4 mg of polysorbate 80 in each ml of solution. Polysorbates can cause allergic reactions. Tell your doctor if you have any known allergies.
Bimzelx contains sodium
This medicine contains less than 1 mmol (23 mg) of sodium per dose, which is essentially "sodium-free".
Follow the instructions for administration of this medicine exactly as told by your doctor or pharmacist. If you are unsure, ask your doctor or pharmacist again.
How much Bimzelx to use and for how long
Plaque psoriasis
The recommended dose, given as injections under the skin ("subcutaneous injections"), is as follows:
Psoriatic arthritis
The recommended dose, given as an injection under the skin ("subcutaneous injection"), is as follows:
Axial spondyloarthritis, including non-radiographic axial spondyloarthritis and ankylosing spondylitis (radiographic axial spondyloarthritis)
The recommended dose, given as an injection under the skin ("subcutaneous injection"), is as follows:
Hidradenitis suppurativa
The recommended dose, given as injections under the skin ("subcutaneous injections"), is as follows:
You and your doctor or nurse will decide if you should inject this medicine yourself. Do not inject this medicine unless a healthcare professional has taught you how to do it. A caregiver can also give you the injections if they have been taught how to do it.
Read the "Instructions for use" at the end of this leaflet before injecting the pre-filled syringe of Bimzelx 160 mg solution for injection yourself.
If you use more Bimzelx than you should
Tell your doctor if you have used more Bimzelx than you should or if you have injected a dose too early.
If you forget to use Bimzelx
Talk to your doctor if you have forgotten to inject a dose of Bimzelx.
If you stop using Bimzelx
Talk to your doctor before stopping the use of Bimzelx. If you stop treatment, the symptoms may come back.
If you have any other questions about the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Serious side effects
Tell your doctor or seek medical attention immediately if you experience any of the following side effects:
Possible serious infection - the signs may include:
Your doctor will decide if you can continue using Bimzelx.
Other side effects
Tell your doctor, pharmacist, or nurse if you experience any of the following side effects:
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if they are not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date is the last day of the month shown.
Store in a refrigerator (2°C - 8°C). Do not freeze.
Keep the pre-filled syringes in the original packaging to protect them from light.
Bimzelx can be stored at room temperature (up to 25°C) for a maximum of 25 days. It must be kept in the outer carton and away from direct light. Do not use the pre-filled syringes after this time. There is a space on the carton for you to write the date you removed it from the refrigerator.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Bimzelx Composition
Appearance of Bimzelx and Container Contents
Bimzelx is a clear to slightly opalescent liquid. The color may vary from colorless to light brownish yellow. It comes in a single-use, disposable prefilled syringe with a needle cap.
Bimzelx 160 mg injectable solution in a prefilled syringe is available in single-unit packages containing 1 or 2 prefilled syringes and in multiple packages with 3 boxes, each containing 1 prefilled syringe, or in multiple packages with 2 boxes, each containing 2 prefilled syringes.
Only some package sizes may be marketed.
Marketing Authorization Holder
UCB Pharma S.A.
Allée de la Recherche 60
B-1070 Bruxelles, Belgium
Manufacturer
UCB Pharma S.A.
Chemin du Foriest
B-1420 Braine-l’Alleud, Belgium
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
België/Belgique/Belgien UCB Pharma S.A./NV Tél/Tel: + 32 / (0)2 559 92 00 | Lietuva UCB Pharma Oy Finland Tel: + 358 9 2514 4221 (Suomija) |
Luxembourg/Luxemburg UCB Pharma S.A./NV Tél/Tel: + 32 / (0)2 559 92 00 (Belgique/Belgien) | |
Ceská republika UCB s.r.o. Tel: + 420 221 773 411 | Magyarország UCB Magyarország Kft. Tel.: + 36-(1) 391 0060 |
Danmark UCB Nordic A/S Tlf.: + 45 / 32 46 24 00 | Malta Pharmasud Ltd. Tel: + 356 / 21 37 64 36 |
Deutschland UCB Pharma GmbH Tel: + 49 /(0) 2173 48 4848 | Nederland UCB Pharma B.V. Tel: + 31 / (0)76-573 11 40 |
Eesti UCB Pharma Oy Finland Tel: + 358 9 2514 4221 (Soome) | Norge UCB Nordic A/S Tlf: + 47 / 67 16 5880 |
Ελλ?δα UCB Α.Ε. Τηλ: + 30 / 2109974000 | Österreich UCB Pharma GmbH Tel: + 43-(0)1 291 80 00 |
España UCB Pharma, S.A. Tel: + 34 / 91 570 34 44 | Polska UCB Pharma Sp. z o.o./VEDIM Sp. z o.o. Tel.: + 48 22 696 99 20 |
France UCB Pharma S.A. Tél: + 33 / (0)1 47 29 44 35 | Portugal UCB Pharma (Produtos Farmacêuticos), Lda Tel: + 351 21 302 53000 |
Hrvatska Medis Adria d.o.o. Tel: +385 (0) 1 230 34 46 | România UCB Pharma Romania S.R.L. Tel: + 40 21 300 29 04 |
Ireland UCB (Pharma) Ireland Ltd. Tel: + 353 / (0)1-46 37 395 | Slovenija Medis, d.o.o. Tel: + 386 1 589 69 00 |
Ísland Vistor hf. Sími: + 354 535 7000 | Slovenská republika UCB s.r.o., organizačná zložka Tel: + 421 (0) 2 5920 2020 |
Italia UCB Pharma S.p.A. Tel: + 39 / 02 300 791 | Suomi/Finland UCB Pharma Oy Finland Puh/Tel: + 358 9 2514 4221 |
Κ?προς Lifepharma (Z.A.M.) Ltd Τηλ: + 357 22 056300 | Sverige UCB Nordic A/S Tel: + 46 / (0) 40 294 900 |
Latvija UCB Pharma Oy Finland Tel: + 358 9 2514 4221 (Somija) |
Date of Last Revision of this Prospectus:
Other Sources of Information
Detailed information about this medication is available on the European Medicines Agency website: https://www.ema.europa.eu
Instructions for Use
Read the following instructions in their entirety before using the Bimzelx 160 mg prefilled syringe.
Bimzelx 160 mg prefilled syringe at a glance (see Figure A):
Important Information:
Do not use this medication and return it to the pharmacy if:
For a more comfortable injection:Remove the 160 mg prefilled syringe(s) from the refrigerator and let it/them sit on a flat surface at room temperature for 30-45 minutesbefore injection.
Follow the steps below each time you use Bimzelx.
Step 1: Prepare the injection(s)
Depending on the prescribed dose, place the following items on a clean, flat, and well-lit work surface, such as a table:
You will also need (not included in the box):
Step 2: Choose the injection site and prepare the injection
2a: Choose the injection site
2b: Wash your hands well with water and soap and dry them with a dry and clean towel
2c: Prepare the skin
2d: Check the prefilled syringe (see Figure D)
Step 3: Inject Bimzelx
3a: Remove the needle cap from the prefilled syringe
3b: Pinch and hold a skin fold that you cleaned for injection with one hand. With the other hand, insert the needle into the skin at an approximate 45-degree angle
3c: Firmly push the plunger head until all the medication is injected (see Figure G)
The medication has been fully injected when it is no longer possible to push the plunger head (see Figure H).
3d: Release your thumb from the plunger head (see Figure I). The needle will automatically retract and lock into place
Step 4: Dispose of the used Bimzelx prefilled syringe
Place the used prefilled syringe in a sharps disposal container immediately after use (see Figure J).
If you need a second injection because it has been prescribed by your doctor, use a new Bimzelx 160 mg prefilled syringe and repeat steps 2-4.
Make sure to select a new injection site for the second injection.